Alteon Announces Investor Update Conference Call Wednesday, May 11, 2005, 4:00 p.m. Eastern time
May 05 2005 - 10:56AM
PR Newswire (US)
Alteon Announces Investor Update Conference Call Wednesday, May 11,
2005, 4:00 p.m. Eastern time --- Conference Call to be Webcast ---
PARSIPPANY, N.J., May 5 /PRNewswire-FirstCall/ -- Alteon Inc.
(AMEX:ALT) announced that it will hold a regularly scheduled
investor update conference call on Wednesday, May 11, 2005 at 4:00
p.m. ET. Anyone interested in participating in the live conference
call should RSVP to Nancy Regan at . There will be a full question
and answer period during the call. The dial-in telephone number for
the conference call will be 1-888-208-1812. International
participants may call +719-457-2654. Participants should call
approximately 5-10 minutes before 4:00 p.m. In addition, the
conference call will be accessible through a webcast on the company
website, http://www.alteon.com/ in the Investor Relations section,
and a digital rebroadcast will be available through May 18, 2005 at
11:59 P.M. by dialing 1-888-203-1112, passcode 9407076 for domestic
callers and +719-457- 0820, passcode 9407076 for international
callers. About Alteon Alteon is developing several new classes of
drugs that have shown the potential to reverse or slow down
diseases of aging and complications of diabetes. These compounds
appear to have an impact on a fundamental pathological process
caused by the progressive formation of protein-glucose complexes
called Advanced Glycation End-products (A.G.E.s). The formation and
crosslinking of A.G.E.s lead to a loss of flexibility and function
in body tissues and organs and have been shown to be a causative
factor in many age- related diseases and diabetic complications.
Alteon has created a library of novel classes of compounds
targeting the A.G.E. pathway. Alteon's lead compound alagebrium
chloride (formerly ALT-711), the only A.G.E. Crosslink Breaker in
advanced human testing, has shown promising results in several
Phase 2 trials and is being developed for systolic hypertension,
heart failure and erectile dysfunction. Approximately 1,300
patients have been involved in alagebrium's human clinical trials
to date, of whom approximately 1,000 have received active compound.
Clinical studies of alagebrium include the Phase 2b systolic
hypertension trial, SPECTRA (Systolic Pressure Efficacy and Safety
Trial of Alagebrium), the Phase 2a heart failure study, PEDESTAL
(Patients with Impaired Ejection Fraction and Diastolic
Dysfunction: Efficacy and Safety Trial of ALagebrium), the Phase 2a
EMERALD study (Evaluation of Alagebrium in Erectile Dysfunction in
Diabetic Males on PDE5 Inhibitors), as well as a fourth study
exploring mechanism of action in endothelial dysfunction. In
February 2005, Alteon voluntarily and temporarily suspended
enrollment of new patients into the Company's ongoing alagebrium
clinical studies pending receipt of additional pre-clinical
toxicity data. In May 2005, the Company announced encouraging
interim results from these ongoing toxicity tests, and announced
its intention to conduct an interim analysis of the SPECTRA trial;
the results of both are expected approximately mid-year 2005. The
Company expects that decisions regarding resumption of enrollment
into each of the trials will be made at that time. For more
detailed information about alagebrium, please visit the research
and development section of the Alteon website,
http://www.alteon.com/. Any statements contained in this press
release that relate to future plans, events or performance are
forward-looking statements that involve risks and uncertainties
including, but not limited to, those relating to technology and
product development (including the possibility that early clinical
trial results may not be predictive of results that will be
obtained in large-scale testing or that any clinical trials will
not demonstrate sufficient safety and efficacy to obtain requisite
approvals or will not result in marketable products), regulatory
approval processes, intellectual property rights and litigation,
competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange
Commission. The information contained in this press release is
accurate as of the date indicated. Actual results, events or
performance may differ materially. Alteon undertakes no obligation
to publicly release the result of any revision to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. DATASOURCE: Alteon Inc. CONTACT: Susan M.
Pietropaolo, Director, Corporate Communications & Investor
Relations, +1-201-934-5000, fax, +1-201-934-8880 Web site:
http://www.alteon.com/
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Ishares Diversified Alternatives Trust (American Stock Exchange): 0 recent articles
More Alteon , News Articles